

# Brett A King

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4586477/brett-a-king-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

2,676  
citations

26  
h-index

49  
g-index

112  
ext. papers

3,777  
ext. citations

4.5  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
92	JAK inhibitors in dermatology: The promise of a new drug class. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 736-744	4.5	207
91	Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 22-28	4.5	170
90	Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. <i>JCI Insight</i> , <b>2016</b> , 1, e89776	9.9	167
89	Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 1110-2	5.1	156
88	Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, 395-9	4.5	147
87	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 242-255	4	137
86	Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 2988-2990	4.3	134
85	Tofacitinib for the treatment of alopecia areata and variants in adolescents. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 29-32	4.5	102
84	A neutrophil activation signature predicts critical illness and mortality in COVID-19. <i>Blood Advances</i> , <b>2021</b> , 5, 1164-1177	7.8	93
83	Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2540-2546	59.2	87
82	Topical Ruxolitinib for the Treatment of Alopecia Universalis. <i>JAMA Dermatology</i> , <b>2016</b> , 152, 490-1	5.1	79
81	Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 806-812.e3	4.5	71
80	Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 736-741	4.5	57
79	Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. <i>JAMA Dermatology</i> , <b>2016</b> , 152, 492-3	5.1	53
78	Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 612-621	4.5	50
77	Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 46-52	4.5	47
76	Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 951-954	4.3	46

75	Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. <i>Blood</i> , <b>2016</b> , 127, 948-51	2.2	42
74	Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. <i>JAAD Case Reports</i> , <b>2018</b> , 4, 443-445	1.4	39
73	Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 403-404.e1	4.5	37
72	Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. <i>JAMA Dermatology</i> , <b>2018</b> , 154, 370-371	5.1	31
71	The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 123-130	4.5	30
70	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 839-846	4.5	30
69	Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 556-558.e1	4.5	29
68	The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 814-826	11.5	29
67	Treatment of Multiorgan Sarcoidosis With Tofacitinib. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 106-109	3.5	28
66	When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, e269-e270	4.5	26
65	Ruxolitinib for the treatment of severe alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 566-568	4.5	24
64	Tofacitinib for the treatment of alopecia areata in preadolescent children. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 568-570	4.5	22
63	Psychophysical measurements of itch and nociceptive sensations in an experimental model of allergic contact dermatitis. <i>Journal of Pain</i> , <b>2015</b> , 16, 741-9	5.2	20
62	Serum sickness-like reaction: histopathology and case report. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, e83-e85	4.5	20
61	Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management. <i>JAMA Dermatology</i> , <b>2018</b> , 154, 1485-1486	5.1	20
60	Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis. <i>JAAD Case Reports</i> , <b>2017</b> , 3, 4-6	1.4	19
59	The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, e223-e226	4.5	19
58	A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 379-387	4.5	18

57	The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 702-709	4	17
56	Treatment of severe lichen planus with the JAK inhibitor tofacitinib. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 1708-1710.e2	11.5	17
55	Lack of efficacy of apremilast in 9 patients with severe alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 773-774	4.5	17
54	Treatment of severe alopecia areata with baricitinib. <i>JAAD Case Reports</i> , <b>2019</b> , 5, 892-894	1.4	16
53	Development of the Scalp Hair Assessment PRO measure for alopecia areata. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 1065-1072	4	15
52	Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 1446-1449.e4	4.3	12
51	Treatment of granuloma annulare with tofacitinib 2% ointment. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 69-71	1.4	12
50	Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 725-732	7.1	12
49	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. <i>JAAD Case Reports</i> , <b>2019</b> , 5, 1018-1026	1.4	12
48	Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 847-853	4.5	12
47	Two Phase 3 Trials of Baricitinib for Alopecia Areata.. <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	12
46	Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 743-745	4.5	11
45	"You lose your hair, what's the big deal?" was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata. <i>Journal of Patient-Reported Outcomes</i> , <b>2020</b> , 4, 76	2.6	11
44	The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature. <i>Yale Journal of Biology and Medicine</i> , <b>2020</b> , 93, 187-195	3.4	11
43	Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib. <i>JAAD Case Reports</i> , <b>2016</b> , 2, 502-504	1.4	10
42	Rethinking the classification of alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, e45	4.5	10
41	Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1795-1809	11.5	10
40	Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 395-405	7.1	9

39	Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream. <i>JAAD Case Reports</i> , <b>2016</b> , 2, 114-6	1.4	9
38	Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 735-736	4.5	8
37	Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 133-135	1.4	8
36	Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, e67-e68	4.5	7
35	Palifermin-associated papular eruption. <i>Archives of Dermatology</i> , <b>2009</b> , 145, 179-82		7
34	The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1594-1601	4.5	7
33	Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims. <i>Advances in Therapy</i> , <b>2021</b> , 38, 4646-4658	4.1	7
32	Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	7
31	Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1778-1779	4.5	6
30	Keratosis lichenoides chronica successfully treated with isotretinoin and methotrexate. <i>JAAD Case Reports</i> , <b>2017</b> , 3, 205-207	1.4	6
29	Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2020</b> , 20, S62-S68	1.1	6
28	A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). <i>JAMA Dermatology</i> , <b>2021</b> , 157, 1-11	5.1	6
27	IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 1731-1734.e1	11.5	5
26	Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 597-599.e2	4.5	5
25	Rule of thumb: A simple tool to estimate 1% scalp surface area. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 630-631	4.5	5
24	Perniolike lesions and coagulopathy in a patient with COVID-19 infection. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 1294-1296	1.4	4
23	Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease. <i>JAAD Case Reports</i> , <b>2021</b> , 7, 44-46	1.4	3
22	Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. <i>JAAD Case Reports</i> , <b>2021</b> , 7, 122-124	1.4	3

21	Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. <i>JAAD Case Reports</i> , <b>2021</b> , 16, 62-64	1.4	3
20	Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 283-284	5.1	2
19	Divalproex sodium: A potential therapy for scleroderma digital ulcers. <i>JAAD Case Reports</i> , <b>2015</b> , 1, 44-5	1.4	2
18	The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2020</b> , 20, S71-S77	1.1	2
17	Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis.. <i>JID Innovations</i> , <b>2021</b> , 1, 100021		2
16	Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework.. <i>Dermatology and Therapy</i> , <b>2022</b> , 1	4	2
15	CD8 mycosis fungoides palmaris et plantaris with peripheral blood involvement. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 434-437	1.4	1
14	Purpuric Lesions on Acral Sites. Type I cryoglobulinemia associated with multiple myeloma. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 659-60	5.1	1
13	A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome (PRO) measures. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	1
12	It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	1
11	Eyebrows Are Important in the Treatment of Alopecia Areata. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , <b>2020</b> , 20, S37-S40	1.1	1
10	Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity?. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, e63-e64	4.5	1
9	A 71-year-old man with a hemorrhagic vesicular eruption. <i>International Journal of Dermatology</i> , <b>2018</b> , 57, 147-148	1.7	1
8	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. <i>PLoS Biology</i> , <b>2021</b> , 19, e3001373	9.7	0
7	Reply to: "Comment on Rule of thumb: A simple tool to estimate 1% scalp surface area Whose thumb is it anyway?". <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, e185	4.5	
6	Repeat Conjunctival Biopsy after Immunomodulatory Therapy for Ocular Mucous Membrane Pemphigoid. <i>Ocular Immunology and Inflammation</i> , <b>2018</b> , 26, 70-73	2.8	
5	STATing the obvious: it's time for new treatments in atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 861-862	4	
4	A unilateral orbital mass. <i>JAMA Dermatology</i> , <b>2014</b> , 150, 1115	5.1	

- 3 The close resemblance between patients with severe alopecia areata and those with cancer: What hair tells us about wellness or grave illness. *Journal of the American Academy of Dermatology*, **2021**, 4.5
- 2 Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata. *Dermatologic Therapy*, **2021**, 34, e15062 2.2
- 1 Electrocardiogram Findings in Patients with Alopecia Areata. *Dermatology and Therapy*, **2021**, 11, 2217-2223 4